Demonstrating the Clinical Potential of Pb-212 Alpha Therapy: Key Learnings from Phase II AlphaMedix Development

9:00 am - Thursday 3rd December 2026

  • Presenting Phase II clinical data evaluating the safety, efficacy and therapeutic potential of Pb-212-based targeted alpha therapies
  • Exploring how clinical findings are shaping patient selection, dosing strategies and future development decisions
  • Examining the key translational and operational learnings generated throughout Phase II development